市場調査レポート
商品コード
1462299
キイトルーダ市場:市場規模、予測、新たな洞察-2032年KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
キイトルーダ市場:市場規模、予測、新たな洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
キイトルーダはモノクローナル抗体であり、PD-1またはPD-L1のいずれかに結合し、PD-1/PD-L1経路を遮断することで免疫反応の阻害を解除し、末梢寛容を破壊し、免疫介在性の副作用を誘発する可能性のある薬剤クラスです。米国FDAはすでにキイトルーダを、メラノーマ、非小細胞肺がん、再発性または転移性の頭頸部がん、古典的ホジキンリンパ腫、尿路上皮がんなど、特定の種類のがんの治療薬として承認しています。卵巣がんの治療薬としては現在も検討中です。
現在、卵巣がんの治療薬として第III相試験が進行中です。キイトルーダはすでに確立され、さまざまな腫瘍タイプで非常に良好な成績を収めているため、同社はさまざまな試験を実施し、さまざまな患者層でこの薬剤の有効性と安全性を検証しています。
今後数年間で、卵巣がんの市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、キイトルーダの優位性に影響を与える可能性のある機会を模索しています。卵巣がんに対する他の新興製品がキイトルーダに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国における卵巣がん治療薬のキイトルーダ市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed picture of the KEYTRUDA for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the KEYTRUDA for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the PD-1 or the PD-L1, blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. The US FDA has already approved KEYTRUDA for the treatment of certain types of cancers, including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer.
The drug is currently being developed in Phase III for the treatment of ovarian cancer. As KEYTRUDA is already established and very well performing in different tumor types, the company is running various trials to test this drug's efficacy and safety in different patient segments in different trials.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
KEYTRUDA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of KEYTRUDA for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of KEYTRUDA for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.